Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common StockGlobeNewsWire • 05/03/22
Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common StockGlobeNewsWire • 05/02/22
Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This YearGlobeNewsWire • 05/02/22
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex BlepharitisGlobeNewsWire • 04/30/22
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business AchievementsGlobeNewsWire • 03/14/22
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical OfficerGlobeNewsWire • 02/03/22
Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03GlobeNewsWire • 02/02/22
Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit FacilityGlobeNewsWire • 02/02/22
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of DirectorsGlobeNewsWire • 01/04/22
Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021GlobeNewsWire • 11/10/21
Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business AchievementsGlobeNewsWire • 11/09/21
Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual MeetingGlobeNewsWire • 11/04/21
Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare ConferenceGlobeNewsWire • 11/02/21
Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of DirectorsGlobeNewsWire • 08/12/21
Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical UpdatesGlobeNewsWire • 08/04/21
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021GlobeNewsWire • 07/24/21
Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare ConferenceGlobeNewsWire • 07/07/21
Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation ConferenceGlobeNewsWire • 06/22/21
Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis StudyBenzinga • 06/21/21
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex BlepharitisGlobeNewsWire • 06/21/21
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex BlepharitisGlobeNewsWire • 06/18/21
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme DiseaseGlobeNewsWire • 06/16/21